Statement: the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed.
Primary_evidence: Adverse Events 1:   Total: 15/122 (12.30%)   febrile neutropenia 4/122 (3.28%)   Neutropenia 0/122 (0.00%)   Angina unstable 1/122 (0.82%)   Coronary artery disease 1/122 (0.82%)   Myocardial infarction 1/122 (0.82%)   Diarrhoea 2/122 (1.64%)   Colitis 1/122 (0.82%)   Pyrexia 2/122 (1.64%)   Chest pain 1/122 (0.82%)   Pneumonia 1/122 (0.82%)   Catheter site cellulitis 1/122 (0.82%) Adverse Events 2:   Total: 7/34 (20.59%)   febrile neutropenia 1/34 (2.94%)   Neutropenia 1/34 (2.94%)   Angina unstable 0/34 (0.00%)   Coronary artery disease 0/34 (0.00%)   Myocardial infarction 0/34 (0.00%)   Diarrhoea 0/34 (0.00%)   Colitis 0/34 (0.00%)   Pyrexia 0/34 (0.00%)   Chest pain 0/34 (0.00%)   Pneumonia 1/34 (2.94%)   Catheter site cellulitis 0/34 (0.00%)   Infection 1/34 (2.94%)
Secondary_evidence: Adverse Events 1:   Total: 17/65 (26.15%)   Febrile neutropenia 3/65 (4.62%)   Neutropenia 2/65 (3.08%)   Pancytopenia 1/65 (1.54%)   Thrombocytopenia 1/65 (1.54%)   Cardiac arrest 2/65 (3.08%)   Myocardial infarction 1/65 (1.54%)   Diarrhoea 5/65 (7.69%)   Stomatitis 1/65 (1.54%)   Vomiting 2/65 (3.08%)   Fatigue 1/65 (1.54%)   Jaundice 1/65 (1.54%)   Neutropenic infection 2/65 (3.08%)